相关实验视频
Updated: May 2, 2026

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
22.3K
低剂量与标准剂量的阿尔泰酶治疗急性缺血性中风:一个现实世界的单中心回顾性研究
Xin-Lei Mao1, Si-Si He1, Ya-Xi Zhang1
1Department of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Frontiers in neurology
|November 6, 2025
概括
在急性缺血性中风 (AIS) 患者中,低剂量 (0.6 mg/kg) 静脉输入的阿尔特拉斯与标准剂量 (0.9 mg/kg) 的阿尔特拉斯相比,显示出类似的90天功能结果和症状性内出血率. 医生的经验和患者因素影响了剂量选择,表明复杂的现实世界治疗决策.
科学领域:
- 神经学 神经学
- 紧急医疗 紧急医疗
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉输入的阿尔特等是急性缺血性中风 (AIS) 的关键治疗方法.
- 现实世界的使用模式和不同阿尔特雷剂量策略的结果需要调查.
- 治疗决策的变化可能会影响患者的护理.
研究的目的:
- 在AIS患者中,比较低剂量 (0.6毫克/公斤) 与标准剂量 (0.9毫克/公斤) 静脉注射高高的实际使用模式和临床结果.
- 分析影响选择阿尔特普拉斯剂量的因素.
- 评估剂量对功能结果和症状性内出血 (sICH) 的影响.
主要方法:
- 一个单一中心的回顾性研究,对707名AIS患者进行了静脉输血栓溶解.
- 基线特征的分析,治疗选择 (低剂量与标准剂量的高剂量) 和临床结果.
- 主要结局包括90天功能结局 (mRS 0-1,mRS 0-2) 和sICH发病率.
主要成果:
- 在老年患者和在中风前服用抗血栓药物的患者中,低剂量阿尔泰拉斯更频繁地使用.
- 初级医生比高级医生更有可能使用低剂量阿尔特普拉斯.
- 在低剂量和标准剂量高甲酶组之间,在90天的功能结果或SICH率上没有观察到显著差异.
结论:
- 在AIS中,静脉输入高高酶的治疗决定是复杂的,受患者和医生因素的影响.
- 在这个现实世界队列中,低剂量阿尔特等产生了与标准剂量阿尔特等相似的临床结果.
- 未来的研究应该旨在优化治疗决策,提高患者遵守指南,以改善患者的治疗结果.
相关概念视频
Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Cardiopulmonary Resuscitation IV: Pharmacological Management
1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632

